CD4 and type 1 diabetes mellitus: Recently, more attention has been focused on various treatments to prevent the destructive activity of CD4+ T cells (Bediaga et al., 2022), as our study showed that astilbin can effectively inhibit the activity of CD4+ T cells in NOD mice and humans, providing a new idea for the treatment of T1D.